Switch theme
Sign up to access all valuation multiples
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
2011
25
LTM Revenue n/a
LTM EBITDA n/a
$64.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Renovaro has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Renovaro achieved revenue of n/a and an EBITDA of -$78.1M.
Renovaro expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Renovaro valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$38.9M | -$78.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$113M | -$39.7M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | $2.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Renovaro's stock price is $0.
Renovaro has current market cap of $58.2M, and EV of $64.3M.
See Renovaro trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.3M | $58.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Renovaro has market cap of $58.2M and EV of $64.3M.
Renovaro's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Renovaro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Renovaro and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $64.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | XXX | XXX |
| P/E | -0.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRenovaro's NTM/LTM revenue growth is n/a
Renovaro's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Renovaro's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Renovaro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Renovaro and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 101% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Renovaro acquired XXX companies to date.
Last acquisition by Renovaro was XXXXXXXX, XXXXX XXXXX XXXXXX . Renovaro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Renovaro founded? | Renovaro was founded in 2011. |
| Where is Renovaro headquartered? | Renovaro is headquartered in United States of America. |
| How many employees does Renovaro have? | As of today, Renovaro has 25 employees. |
| Who is the CEO of Renovaro? | Renovaro's CEO is Mr. David Weinstein. |
| Is Renovaro publicy listed? | Yes, Renovaro is a public company listed on NAS. |
| What is the stock symbol of Renovaro? | Renovaro trades under RENB ticker. |
| When did Renovaro go public? | Renovaro went public in 2014. |
| Who are competitors of Renovaro? | Similar companies to Renovaro include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Renovaro? | Renovaro's current market cap is $58.2M |
| Is Renovaro profitable? | Yes, Renovaro is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
